baber/WOPTO huggingface dataset:
Patent NZ-221796-A (NZ)
Title: Regenerating colour burst from shortened burst: clock and lock
Inventor: KATZNELSON R D
IPC: H04N9/455
Filed: 1987-09-14
Abstract: A system for regenerating a standard-length color burst signal from a less-than-standard-length color burst information signal of a given frequency and phase. The system includes a phase-locked loop (20) for generating a system clock signal(46) from the color burst information signal (42), with the clock signal having a clock frequency related to and at least twice the given frequency of the color burst information signal. The phase information from the color burst information signal is sampled and stored in a RAM (26). The sampling is clocked by the system clock signal. A standard-length color burst signal (58) is regenerated at the given frequency and in phase with the color burst information signal by retrieving the stored phase information and extrapolating the standard-length signal in accordance with the retrieved phase information. Such retrieval is clocked by the system signal. The phase-locked loop is a digital phase-locked loop; and the color burst information signal is converted into a digital color burst information signal for processing by the phase-locked loop and for sampling and retrieval of the phase information. Upon retrieval and extrapolation of the phase information samples, the retrieved and extrapolated phase information samples (54) are converted into an analog sample information signal (56), which is converted into a regenerated sinusoidal standard-length color burst signal (58) by a low pass filter (34).
Patent NZ-227518-A (NZ)
Title: Antihypertensive composition of a potassium channel activator and a beta-blocker
Inventor: EVANS JOHN MORRIS
IPC: A61K31/13
Filed: 1989-01-05
Abstract: A pharmaceutical product comprising a potassium channel activator antihypertensive agent and a  beta -blocker antihypertensive agent as a combined preparation for simultaneous, separate or sequential use in therapy of hypertension.
Patent NZ-229144-A (NZ)
Title: Substituted pyrimidinedione derivatives and pharmaceutical compositions, and 1-(1-piperazinyl) isoquinoline as an intermediate reagent
Inventor: FROST JONATHAN
IPC: C07D401/12
Filed: 1989-05-16
Abstract: Compounds corresponding to the general formula (I) 
<IMAGE>
 in which R1 denotes a hydrogen or halogen atom or a methyl or methoxy group, R2 denotes a hydrogen atom, a C1-C4 alkyl group or a benzyl group, n denotes an integer equal to 2, 3 or 4, X denotes a CH group or a nitrogen atom, and R3 denotes a hydrogen or halogen atom or a methoxy group. 
<??>Application in therapeutics.
Patent NZ-232879-A (NZ)
Title: Multi-unit package for parallelepiped cartons
Inventor: SAULAS ALAIN
IPC: B65D5/02
Filed: 1990-03-12
Abstract: A package which accommodates a plurality of parallelapiped cartons (B) comprises a sleeve including a top wall panel (14) and a bottom wall panel (18) interconnected by spaced side wall panels (12, 16) thereby forming a tubular structure in which the parallelapiped cartons are accommodated. The tubular structure includes end wall panels (28, 36; 26, 34) which at least partially close the ends of the tubular structure. Corners of the sleeve each formed in part by a side wall panel and an adjacent end wall panel extend substantially the full height of the packaged cartons adjacent to such corners and upper and lower edges of each side wall panel adjacent upper and lower portions of the sleeve corners are each formed with a recess. The recesses of one sleeve are sized and positioned to receive said upper and lower corner portions (C) of a like adjacent sleeve so that the adjacent sleeves can be nested when in flat form.
Patent NZ-233652-A (NZ)
Title: Catalytic reaction of carbon monoxide and hydrogen to yield hydrocarbons with a cobalt containing catalyst
Inventor: POST MARTIN FRANCISCUS MARIA
IPC: C07B37/02
Filed: 1990-05-11
Abstract: The invention relates to a process for the preparation of hydrocarbons by catalytic reaction of carbon monoxide with hydrogen, comprising the steps of:     a) selecting a catalyst comprising:   i) 3-80 parts by weight cobalt per 100 parts by weight of porous carrier; ii) 0.1-100 parts by weight of at least one metal selected from zirconium, titanium and chromium, per 100 parts by weight of porous carrier; and   iii) an external surface area (Se)  Se </= 70 cm<2>/ml;     b) activating the catalyst; and c) contacting the activated catalyst in a fixed bed form with a mixture of carbon monoxide and hydrogen having a hydrogen/carbon monoxide feed ratio (F)  F </= 1.9  under such conditions that  Se/F >/= 12.5, and to hydrocarbons obtained therewith.
Patent NZ-242443-A (NZ)
Title: Method of using an aromatose inhibitor for contraception in female primates
Inventor: BHATNAGER AJAY
IPC: A61K31/415
Filed: 1992-04-22
Abstract: The invention relates to the use of aromatase inhibitors for contraception in female primates and to a method for contraception in female primates using such substances and to the use of those substances for the preparation of pharmaceutical compositions for contraception in female primates.
Patent NZ-260298-A (NZ)
Title: 1h-indol-3-ylacetamide and -thioacetamide derivatives and pharmaceutical compositions
Inventor: BACH NICHOLAS JAMES
IPC: C07F9/572
Filed: 1994-04-13
Abstract: A class of 1H-indole-3-acetamides, represented by the formula (I), and pharmaceutically acceptable salts thereof; <CHEM> is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
Patent NZ-261640-A (NZ)
Title: Connector, for pipe of plastics with memory, having three different outer diameter pipe contact sections
Inventor: LUNDEQUIST YNGVE
IPC: B21D41/02
Filed: 1994-01-27
Abstract: A method for establishing a connection between one end (8) of a pipe (1) made of a plastic material having memory properties and a flanged connector sleeve (3) of a pipe-connecting piece (2; 11), comprising expanding the pipe-end (8) to an inner diameter which exceeds the outer diameter of the flange, and inserting the flanged connector sleeve (3) into the expanded pipe-end. There is used to this end an expanding tool (15) which comprises a number of movable expander jaws (22) which have an essentially circular-arcuate shape in cross section and which include outer jaw surfaces (27) that are delimited by mutually opposing jaw edges (28) and present recesses, e.g. grooves (32, 33), in the region of the jaw edges (28). As the pipe is expanded, there are formed on the inner surface of the pipe-end (8) inwardly directed beads (30; 31) which interrupt the contact zones between the inner surface of the pipe-end and the outer jaw surfaces (27) in the region of the edges (28) of the expanded jaws (22). The connector sleeve (3) of the connecting piece (2; 11) has provided forwardly of the flange (6) an axially outer, tubular part (5) which has an outer diameter which is at least essentially equal to the inner diameter of the unexpanded plastic pipe (1) and which has a length which is at least equal to the inner diameter of the unexpanded plastic pipe.
Patent NZ-273504-A (NZ)
Title: Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
Inventor: FANSLOW WILLIAM CHRISTIAN
IPC: C12N5/10
Filed: 1994-09-02
Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to CD40 and are capable of blocking binding of CD40 to CD40 ligand.
Patent NZ-286698-A (NZ)
Title: Piperazine, piperidine and 1,2,5,6-tetrahydropyridine derivatives, and pharmaceutical compositions
Inventor: PEGLION JEAN-LOUIS
IPC: A61K31/445
Filed: 1996-05-30
Abstract: Piperazine, piperidine, and tetrahydropyridine derivatives of formula (I), in racemic or optically isomeric or enantiomeric forms, and their salts, are new. A-B = CH2-CH, CH=C, or CH2-N; n = 0 or 1-6; D = a bicyclic system of any of the formulae e.g. (1)-(5); R1, R2 = H, halo, 1-5C alkyl or alkoxy, or OH; E = one of the heterocycles e.g. (a)-(e); with the proviso that E is not (d) when D is (2), (3) or (4), all joined by the 1-position.
Patent NZ-295297-A (NZ)
Title: Polypeptide encoded by an isolated nucleic acid encoding 120-128 kda taga antigen of helicobacter pylori or an antigenic fragment thereof;
Inventor: COVER TIMOTHY L
IPC: C12Q1/68
Filed: 1995-09-29
Abstract: The present invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic polypeptide of the present invention and detecting the binding of the antigen or fragment and the antibody. The detection of a strain expressing the TagA antigen is an indication of predisposition to peptic ulceration and gastric carcinoma. A mutant H. pylori not expressing a functional TagA antigen is also provided.
Patent NZ-307366-A (NZ)
Title: Treatment of mania and bipolar disorders with gabapentin derivatives
Inventor: PANDE ATUL CHANDRA
IPC: A61P25/24
Filed: 1996-04-26
Abstract: The present invention is a novel therapeutic use of gabapentin, its derivatives, and the pharmaceutical salts thereof. The compounds are useful in the treatment of mania in all its various forms whether acute or chronic, single or recurrent, and whether or not it is associated with depression. The invention further includes the treatment of bipolar disorder.
Patent NZ-337194-A (NZ)
Title: Valve cartridge including an actuator which closes the valve with a predetermined pressure and stop means comprising spaced apart lugs
Inventor: BURKE PETER ASHLEY
IPC: F16K31/06
Filed: 1998-01-07
Abstract: A valve cartridge for a tap includes a housing 32 having inlet member 54, outlet member 52  and screw thread 34.  Cavity 36 extends axially through housing 32 within which is a piston 38  which moves axially against piston seal 44 to open and close the tap.  A flow chamber  40  is provided at the end of housing 32 and includes a first seal 42 for sealing against a valve seat in the tap. Piston 38 can be moved axially by either a rotatable spindle 46 or, a solenoid and push rod.  Piston 38 is moved axially without any rotation. Coupling member  84 couples spindle 46 to piston 38 and rotates relative to the piston 38 and the spindle. When spindle 46 is turned a predetermined number of revolutions the coupling 84 causes piston 38 to abut piston seal 44, any further rotation of spindle 46 causes rotation of the coupling member 84 without effecting the axial position of piston 38.  Ratchet members  92, 94, slip past housing splines 102 when the predetermined number of revolution or force is reached.  This limits the sealing pressure of the piston 38  against the piston seal  44  irrespective of the number of turns made of spindle 46.  Stops 64 limits maximum opening and prevents check valve 70 from being forced into sealing contact with inlet member 54.
Patent NZ-501430-A (NZ)
Title: Catalytic conversion of gases via cation-exchangeable alumino-silicate materials
Inventor: MACKINNON IAN DONALD RICHARD
IPC: B01J29/74
Filed: 1998-07-15
Abstract: A process for catalytic conversion and/or adsorption of gases inclusive of NOx, SOx, CO2, CO, dioxins and PAHs and combinations thereof wherein said gases may contain particulates which include contacting one or more of such gases with an alumino-silicate material having: (i) a primarily tetrahedrally coordinated aluminum as established by the fact that the 27Al Magic Angle Spinning (MAS) provides a single peak at 55-58ppm (FWHM=~23ppm) relative to Al(H2O)63+; and (ii) a cation exchange capacity of at least 1meq 100g-1 in aqueous solution at room temperature.
Patent NZ-505643-A (NZ)
Title: Processing of messages in a telecommunication system by monitoring a given memory location in a subscriber indentity module SIM and encrypting or decrypting a message on the basis of a predetermined string stored in a given memory location
Inventor: HEINONEN PETTERI
IPC: H04L9/14
Filed: 1999-01-13
Abstract: The present invention relates to telecommunication systems. The object of the present invention is to disclose a new type of procedure and system for encrypting the outgoing message traffic between mobile stations consistent with current mobile communication standards and/or between a mobile station and a service provider and for decrypting the incoming message traffic. In addition, the procedure and system of the invention allow encrypted messages to be sent to and received from a closed receiver group in a given area.
Patent NZ-509228-A (NZ)
Title: Attenuated pestiviruses
Inventor: MEYERS GREGOR
IPC: A61K35/13
Filed: 1999-05-26
Abstract: Attenuated pestiviruses wherein the RNase activity residing in glycoprotein ERNS is inactivated by mutations/deletions; and their use in vaccines.
Patent NZ-511310-A (NZ)
Title: Absorbent product with an end portion having arcuate long sides
Inventor: DREVIK SOLGUN
IPC: A61F5/44
Filed: 1999-11-15
Abstract: An absorbent product such as a sanitary towel, incontinence protection, or protection for briefs, which has an essentially elongate shape with a longitudinal and a transverse direction, an upper and a lower side, and has a first end portion intended to face forwards on the wearer and a second end portion intended to face backwards on the wearer. The first end portion has greater width than the second end portion which has a maximum width of 40 mm.  The long sides of this end portion are arcuate and curved inwards towards the longitudinal centre line of the product.
Patent NZ-514267-A (NZ)
Title: Pharmaceutical compounds
Inventor: DEL SOLDATO PIERO
IPC: C07D495/04
Filed: 2000-04-11
Abstract: A compound or its salts thereof has the formula (I) A-B-C-N(O)2 wherein: A is R-T1-; R is radical of a drug such that A has the formula R-T1-Z or R-T1-OZ; Z is H or alkyl; T1 is (CO)t or (X)t'; X is O, S, NR1C; R1C is H, alkyl, or a free valence; t and t' are independently 0 or 1 provided that that t is 1 when t' is 0 and t is 0 when t' is 1; B is -TB-X2-TBI-; TB is (CO) when t is 0 or TB is X when t' is 0; TBI is (CO)tx or (X)txx; tx and txx are independently 0 or 1 provided that tx is 1 when txx is 0, and tx is 0 when txx is 1; X2 is a bivalent bridging group as defined in the specification such that the group B is L-carnosine, pencillamine, N-aceytalpenicillamine, cysteine, N-acetylcysteine, gallic acid, ferulic acid, gentisic acid, caffeic acid, hydro caffeic acid, p-coumaric acid, vanillic acid, suringic acid, hydroquinone, methoxyhydroquinone, hydroxyhydroquinone, hydroxyphenetyl alcohol and p-coumaric alcohol; C is -TC-Y-; Tc is (CO) when tx is 0 or is X when txx is 0; Y is alkyloxy or optionally substituted cycloalkylene ring wherein one of the carbon atoms can be replaced by a heteroatom or Y is -[C(RTIX)(RTIX')]nIX-Y3-C(RTIIX)(RTIIX')]nIIx; RTIX, RTIX', nIX, Y3, RTIIX, RTIIX' and nIIx are as defined in the specification. The drug is defined in the specification and can be an anti-inflammatory drug such as aceclofenac, analgesic drug such as acetaminophen, bronchodilator and drug active on the cholinergic system such as acefylline, expectorant/mucolytic drug such as ambroxol, antiasthmatic/antiallergic antihistaminic drug such as acrivastine, ACE-inhibitor such as alacepril, beta-blocker such as acebutolol, vasoactive drug such as acetorphan, antidiabetic drug such as acarbose, antitumoral drug such as ancitabine, antiulcer drug such as arbaprostil, antibiotic such as amdinocillin, antiviral drug such as acyclovir, bone resorption inhibitor such as alendronic acid, antidementia drug such as amiridine.
Patent NZ-514306-A (NZ)
Title: Methods for treating osteoarthritis using dihydronapthalene or benzopyran derivatives with a further inclusion of COX-2 inhibitors
Inventor: LITTMAN BRUCE HENRY
IPC: A61K31/454
Filed: 2001-09-20
Abstract: An estrogen agonist/antagonist of the compound of formula (I) wherein:  A is CH2 or NR B, D and E are CH or N Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4, (b) napthyl, optionally substituted with 1-3 substituents independently selected from R4, (c ) C3-C8 cycloalkyl optionally substituted with 1-2 substituents independently selected from R4, (d) C3-C8 cycloalkenyl optionally substituted with 1-2 substituents independently selected from R4, (e) a five membered heterocycle with up to 2 heteroatoms selected from ûO-, -NR2 and ûS(O)n-, optionally substituted with 1-3 substituents independently selected from R4Æ, (f) a six membered heterocycle with up to 2 heteroatoms selected from ûO-, -NR2 and ûS(O)n-, optionally substituted with 1-3 substituents independently selected from R4 or (g) a bicyclic ring system consisting of five or six membered heterocycle ring fused to a phenyl ring, with the heterocycle ring containing up to 2 heteroatoms selected from ûO-, -NR2 and ûS(O)n-, optionally substituted with 1-3 substituents independently selected from R4 Z1 is û(CH2)pW(CH2)q-, -O(CH2)pCR5R6-, -O(CH2)pW(CH2)q-, -OCHR2CHR3- or ûSCHR2CHR3- G is ûNR7R8 , formula (II) wherein n is 0,1 or 2, m is 1,2 or 3 Z2 is ûNH-, -O-, -S- or ûCH2-, or a bicyclic amine containing 5 to 12 carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4 or Z1 and G in combination may be formula (III) W is ûCH2-, -CH=CH-, -O-, -NR2-, -S(O)n-,-C(O)-, -CR2(OH)-, -CONR2-, -NR2CO-, -C¦C- or formula (IV) R is H or C1-C6 alkyl R2 and R3 are H or C1-C4 alkyl R4 is H, halogen, alkyl, alkoxy, acyloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxy alkyl, aryl alkyl, -CO2H-, -CN, -CONHOR, -SO2NHR, -NH2, alkylamino, diakylamino, -NHSO2R, -NO2, aryl or OH R5 and R6 are C1-C8 alkyl or together form a C3-C10 carbocyclic ring R7 and R8 are phenyl, carbocyclic ring saturated or unsaturated, heterocyclic ring containing up to 2 heteroatoms selected from ûO-, -N- and ûS-, H, alkyl or form a 3 to 8 membered nitrogen containing ring with R5 or R6. R7 and R8 in either linear or ring form may optionally be substituted with up to 3 substituents independently selected from alkyl, halogen, alkoxy, hydroxy and carboxy. A ring formed by R7 and R8 may be optionally fused to a phenyl ring e and n are 0, 1 or 2 m is 1,2 or 3 p and q are 0, 1, 2 or 3 is useful in the treatment of osteoarthritis.
Patent NZ-514657-A (NZ)
Title: Production of pancreatic procarboxy-peptidase B, isoforms and muteins thereof, and their use
Inventor: HABERMANN PAUL
IPC: C12N15/57
Filed: 2000-03-23
Abstract: The preparation of carboxypeptidase B and procarboxypeptidase B. Also the use of procarboxypeptidase B for the preparation of carboxypeptidase B. Pancreatic carboxypeptidase B or an isoform or a mutein of carboxypeptidase B may be prepared by (a) expressing a natural or unnatural enzymatically inactive precursor form of carboxypeptidase B in a microorganism by secretion, (b) purifying the precursor form expressed by secretion, and (c) converting the purified precursor form into the active form by an enzymatic treatment. A nucleic acid construct and a host cell containing the construct are useful for preparing pancreatic carboxypeptidase B or an isoform or a mutein thereof by this method
Patent NZ-516908-A (NZ)
Title: High speed variable size toaster
Inventor: JONES DOUGLAS
IPC: F24C15/32
Filed: 2000-08-04
Abstract: A cooking appliance (11) which is capable of rapidly toasting a food product disposed therein by means of air impingement and infrared heating to provide a cooked food product having the desired color and crunchiness about its surface. The appliance (11) is particularly adapted for cooking sandwich products, toasting the bread and heating the sandwich filler. The appliance includes an air impingement assembly (17B) that delivers columns of heated air to the food product and an infrared heater assembly (19) that produces infrared energy. The appliance delivers the impingement air from above the food product and the infrared energy from below. Alternatively, the appliance delivers the impingement air from above and below the food product and the infrared energy from below.
Patent NZ-519633-A (NZ)
Title: Composition containing xylitol, gum and fibre for use in foodstuffs and beverages
Inventor: GARE FRAN
IPC: A23L29/269
Filed: 2002-06-18
Abstract: A food composition without any artificial sweeteners or sugar comprises a sugarless natural sweetening agent comprising xylitol having particular functional properties; a whey protein in an amount between 0.1% to about 40% by weight; a gum; and at least one fiber to provide additional bulk without adding calorific value, for use in a recipe to produce a flour and sugar-free product. Also described is a diabetic food composition free of artificial sweeteners, flours and sugar for use in a recipe to prepare a sugar-free foodstuff the food composition comprises a sugarless natural sweetening agent comprising xylitol having particular functional properties; a whey protein in an amount between 0.1% to about 40% by weight; a non-toxic soluble or insoluble salt; a low carbohydrate flavoring; a gum; and at least one fiber to provide additional bulk without adding calorific value. Preferably the food product is a bakery product, a dairy product, a snack bar, a salad dressing, a candy, a topping or a beverage.
Patent NZ-523807-A (NZ)
Title: Substituted-triazolopyrimidines as anticancer agents
Inventor: SCHMITT MARK R
IPC: A61K31/541
Filed: 2001-06-28
Abstract: Use of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof for treating of inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof is disclosed, these substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof are also useful for treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promoting microtubule polymerization.
Patent NZ-524280-A (NZ)
Title: A retroviral immunotherapy
Inventor: ASHDOWN MARTIN LEONARD
IPC: A61P35/02
Filed: 2001-08-16
Abstract: It was noted that at least two populations of immune cells are produced in response to retroviruses which infect mammals. More particularly, the immune system of a mammal infected with a retrovirus is capable of mounting an immune response against the virus through a group of cells referred to as "effector cells", however, a second population of cells are also produced that regulate the "effector cells" - referred to as "regulator cells" - limiting the mammals' ability to effectively control or eradicate the retroviral infection. Accordingly, these observations have provided the method for manufacturing medicaments for treating a mammal with a retroviral infection.
Patent NZ-527557-A (NZ)
Title: Degradation of epothilones and ethynyl substituted epothilones
Inventor: HOEFLE GERHARD
IPC: C12P17/00
Filed: 2002-02-27
Abstract: A process for a degradation of an epothilone C or an epothilone D, wherein an epothilone C or epothilone D is subjected to an olefin metathesis in the presence of ethylene and subsequently an optional ester hydrolysis is disclosed. Further, a process for the preparation of 2-methyl-1,3-thiazol-4-yl)-ethynyl substituted epothilones is also described.
Patent NZ-528081-A (NZ)
Title: Novel benzoylguanidine salt
Inventor: EICKMEIER CHRISTIAN
IPC: A61P13/12
Filed: 2002-02-14
Abstract: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethyl-benzoylguanidine hydrochloride of formula (I), a method for the production thereof and the use of the same for producing a pharmaceutical is disclosed.